OWP PHARMS
PharmaOWP PHARMS is a pharmaceutical company focused on Neurology. Key products include SUBVENITE.
OWP PHARMS's Key Drugs
OWP PHARMS's core commercial portfolio centers on SUBVENITE, spanning Neurology — its most strategically important drugs approved in the last 15 years.
OWP PHARMS's Recent FDA Approvals
OWP PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
OWP PHARMS's Therapeutic Areas
OWP PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OWP PHARMS's Top Competitors
OWP PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OWP PHARMS Pipeline Snapshot
Active clinical trials for OWP PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SUBVENITE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-09-16
- Latest
- 2025-09-16
- Applications
- 1